Hua Medicine (“the Company”stock code: 2552. HK) revealed today that the Company provided the current research study outcomes of dorzagliatin, its worldwide first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). A preclinical animal research study revealed that the mix of dorzagliatin and sitagliptin, a DPP-4 inhibitor, enhances blood sugar levels, promotes insulin secretion, and improves GLP-1 secretion. The mix treatment was more reliable than dorzagliatin alone. The blood chemistry analysis even more suggests that the mix treatment has possible advantages for lipid lowering (particularly LDL) (See Figure 1).
Dorzagliatin is the world’s very first glucokinase activator individually established by Hua Medicine, intending to bring back the imbalanced blood sugar levels in clients with type 2 diabetes by fixing the impaired function and expression of glucokinase and improving glucose level of sensitivity in clients with type 2 diabetes. Sitagliptin, a DPP4 inhibitor, enhances glucose control by obstructing destruction of GLP-1. This research study intends to examine the effect of long-lasting administration of dorzagliatin and the mix of dorzagliatin/sitagliptin on glucose homeostasis in high-fat diet-induced obesity/diabetes (DIO) mice.
In the research study, the DIO mice were administered dorzagliatin at a dose of 30 mg/Kg/day, or a mix of dorzagliatin (very same dosage) and sitagliptin (20mg/Kg/day) for 30 days. Mice on a basic diet plan worked as controls. On day 30, the glucose levels were all decreased compared to pre-treatment, and the mix treatment was more efficient than dorzagliatin alone. Dorzagliatin monotherapy promoted insulin and GLP-1 secretion, and the mix led to an additional boost.
Blood biochemical analysis revealed that drug treatment substantially enhanced glycated serum protein (GSP) in DIO mice. Mix treatment likewise enhanced low-density lipoprotein (LDL) levels. LDL transportations cholesterol to arteries, and extreme LDL can trigger arteriosclerosis, myocardial infarction, stroke, and peripheral arterial illness. These outcomes recommend that mix treatment has possible advantages decreasing blood lipids (specifically LDL) while bring back glucose homeostasis, checking out possibilities for scientific medication and brand-new indicator growth.
Figure 1 Blood Biochemical 2025 ADA 893-P
Another investigator-initiated real-world research study was likewise provided at the ADA conference. This single-center potential observational research study intended to examine the short-term effectiveness and hidden systems of dorzagliatin in T2DM clients. Interim analysis revealed substantial decreases in HbA1c levels, enhancements in constant glucose tracking specifications, and defense of β-cell insulin secretion capability as shown by β-cell function indices (See Figure 2). The essential analysis information are as follows:
HbA1c
– reduced substantially from 8.1 ± 1.2% at standard to 7.3 ± 1.1 %at 3 months
– sustained the decrease to 7.3 ± 1.1% at 6 months (both p<
